IDEXX LABORATORIES INC (IDXX) Fundamental Analysis & Valuation

NASDAQ:IDXX • US45168D1046

Current stock price

560.8 USD
+7.14 (+1.29%)
At close:
563.6 USD
+2.8 (+0.5%)
After Hours:

This IDXX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. IDXX Profitability Analysis

1.1 Basic Checks

  • In the past year IDXX was profitable.
  • In the past year IDXX had a positive cash flow from operations.
  • IDXX had positive earnings in each of the past 5 years.
  • IDXX had a positive operating cash flow in each of the past 5 years.
IDXX Yearly Net Income VS EBIT VS OCF VS FCFIDXX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

1.2 Ratios

  • IDXX has a Return On Assets of 31.62%. This is amongst the best in the industry. IDXX outperforms 98.93% of its industry peers.
  • The Return On Equity of IDXX (65.99%) is better than 99.47% of its industry peers.
  • IDXX's Return On Invested Capital of 41.85% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 9.14%.
  • The 3 year average ROIC (37.64%) for IDXX is below the current ROIC(41.85%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 31.62%
ROE 65.99%
ROIC 41.85%
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.64%
ROIC(5y)38.05%
IDXX Yearly ROA, ROE, ROICIDXX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

1.3 Margins

  • The Profit Margin of IDXX (24.62%) is better than 95.19% of its industry peers.
  • In the last couple of years the Profit Margin of IDXX has grown nicely.
  • IDXX has a Operating Margin of 31.60%. This is amongst the best in the industry. IDXX outperforms 98.93% of its industry peers.
  • IDXX's Operating Margin has improved in the last couple of years.
  • IDXX's Gross Margin of 61.80% is fine compared to the rest of the industry. IDXX outperforms 62.03% of its industry peers.
  • In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
Industry RankSector Rank
OM 31.6%
PM (TTM) 24.62%
GM 61.8%
OM growth 3Y5.77%
OM growth 5Y4.3%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
IDXX Yearly Profit, Operating, Gross MarginsIDXX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IDXX Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IDXX is creating value.
  • Compared to 1 year ago, IDXX has less shares outstanding
  • Compared to 5 years ago, IDXX has less shares outstanding
  • The debt/assets ratio for IDXX has been reduced compared to a year ago.
IDXX Yearly Shares OutstandingIDXX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IDXX Yearly Total Debt VS Total AssetsIDXX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

2.2 Solvency

  • An Altman-Z score of 20.51 indicates that IDXX is not in any danger for bankruptcy at the moment.
  • IDXX's Altman-Z score of 20.51 is amongst the best of the industry. IDXX outperforms 94.12% of its industry peers.
  • IDXX has a debt to FCF ratio of 0.81. This is a very positive value and a sign of high solvency as it would only need 0.81 years to pay back of all of its debts.
  • With an excellent Debt to FCF ratio value of 0.81, IDXX belongs to the best of the industry, outperforming 90.37% of the companies in the same industry.
  • IDXX has a Debt/Equity ratio of 0.48. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.48, IDXX perfoms like the industry average, outperforming 40.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 0.81
Altman-Z 20.51
ROIC/WACC4.67
WACC8.96%
IDXX Yearly LT Debt VS Equity VS FCFIDXX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B 1.5B

2.3 Liquidity

  • A Current Ratio of 1.23 indicates that IDXX should not have too much problems paying its short term obligations.
  • The Current ratio of IDXX (1.23) is worse than 86.63% of its industry peers.
  • IDXX has a Quick Ratio of 1.23. This is a bad value and indicates that IDXX is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of IDXX (0.90) is worse than 84.49% of its industry peers.
  • The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 0.9
IDXX Yearly Current Assets VS Current LiabilitesIDXX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. IDXX Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 16.18% over the past year.
  • IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 14.26% yearly.
  • IDXX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.42%.
  • Measured over the past years, IDXX shows a quite strong growth in Revenue. The Revenue has been growing by 9.72% on average per year.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%

3.2 Future

  • Based on estimates for the next years, IDXX will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.69% on average per year.
  • IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.94% yearly.
EPS Next Y13.3%
EPS Next 2Y13.11%
EPS Next 3Y13.25%
EPS Next 5Y12.69%
Revenue Next Year9.17%
Revenue Next 2Y8.88%
Revenue Next 3Y9%
Revenue Next 5Y8.94%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IDXX Yearly Revenue VS EstimatesIDXX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B 8B
IDXX Yearly EPS VS EstimatesIDXX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

4

4. IDXX Valuation Analysis

4.1 Price/Earnings Ratio

  • IDXX is valuated quite expensively with a Price/Earnings ratio of 42.91.
  • Based on the Price/Earnings ratio, IDXX is valued a bit cheaper than the industry average as 67.38% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.77. IDXX is valued rather expensively when compared to this.
  • A Price/Forward Earnings ratio of 37.87 indicates a quite expensive valuation of IDXX.
  • 70.05% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
  • IDXX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.75.
Industry RankSector Rank
PE 42.91
Fwd PE 37.87
IDXX Price Earnings VS Forward Price EarningsIDXX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • IDXX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. IDXX is cheaper than 68.98% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, IDXX is valued a bit cheaper than 73.80% of the companies in the same industry.
Industry RankSector Rank
P/FCF 42.68
EV/EBITDA 29.39
IDXX Per share dataIDXX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of IDXX may justify a higher PE ratio.
  • A more expensive valuation may be justified as IDXX's earnings are expected to grow with 13.25% in the coming years.
PEG (NY)3.23
PEG (5Y)3.01
EPS Next 2Y13.11%
EPS Next 3Y13.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDXX Dividend Analysis

5.1 Amount

  • No dividends for IDXX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDXX Fundamentals: All Metrics, Ratios and Statistics

IDEXX LABORATORIES INC

NASDAQ:IDXX (4/30/2026, 5:49:42 PM)

After market: 563.6 +2.8 (+0.5%)

560.8

+7.14 (+1.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Industry Strength11.18
Industry Growth60.87
Earnings (Last)02-02
Earnings (Next)05-05
Inst Owners95.6%
Inst Owner Change-0.01%
Ins Owners0.21%
Ins Owner Change1.92%
Market Cap44.54B
Revenue(TTM)4.30B
Net Income(TTM)1.06B
Analysts80.91
Price Target755.47 (34.71%)
Short Float %2.62%
Short Ratio4
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.79%
Min EPS beat(2)3.12%
Max EPS beat(2)6.47%
EPS beat(4)4
Avg EPS beat(4)4.78%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.3%
EPS beat(12)12
Avg EPS beat(12)4.65%
EPS beat(16)14
Avg EPS beat(16)3.71%
Revenue beat(2)1
Avg Revenue beat(2)0.36%
Min Revenue beat(2)-0.31%
Max Revenue beat(2)1.03%
Revenue beat(4)2
Avg Revenue beat(4)0.17%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.74%
Revenue beat(12)3
Avg Revenue beat(12)-1%
Revenue beat(16)3
Avg Revenue beat(16)-1.15%
PT rev (1m)-1.71%
PT rev (3m)-3.58%
EPS NQ rev (1m)-0.29%
EPS NQ rev (3m)-0.58%
EPS NY rev (1m)-0.1%
EPS NY rev (3m)0.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.42%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.42%
Valuation
Industry RankSector Rank
PE 42.91
Fwd PE 37.87
P/S 10.35
P/FCF 42.68
P/OCF 37.69
P/B 27.74
P/tB 41.18
EV/EBITDA 29.39
EPS(TTM)13.07
EY2.33%
EPS(NY)14.81
Fwd EY2.64%
FCF(TTM)13.14
FCFY2.34%
OCF(TTM)14.88
OCFY2.65%
SpS54.19
BVpS20.21
TBVpS13.62
PEG (NY)3.23
PEG (5Y)3.01
Graham Number77.0998 (-86.25%)
Profitability
Industry RankSector Rank
ROA 31.62%
ROE 65.99%
ROCE 61.77%
ROIC 41.85%
ROICexc 44.96%
ROICexgc 57.39%
OM 31.6%
PM (TTM) 24.62%
GM 61.8%
FCFM 24.25%
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.64%
ROIC(5y)38.05%
ROICexc(3y)42.76%
ROICexc(5y)42.28%
ROICexgc(3y)54.98%
ROICexgc(5y)55.56%
ROCE(3y)53.48%
ROCE(5y)55.19%
ROICexgc growth 3Y6.58%
ROICexgc growth 5Y1.33%
ROICexc growth 3Y7.31%
ROICexc growth 5Y1.49%
OM growth 3Y5.77%
OM growth 5Y4.3%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 0.81
Debt/EBITDA 0.51
Cap/Depr 95.21%
Cap/Sales 3.21%
Interest Coverage 36.08
Cash Conversion 78.51%
Profit Quality 98.5%
Current Ratio 1.23
Quick Ratio 0.9
Altman-Z 20.51
F-Score8
WACC8.96%
ROIC/WACC4.67
Cap/Depr(3y)104.09%
Cap/Depr(5y)113.7%
Cap/Sales(3y)3.41%
Cap/Sales(5y)3.73%
Profit Quality(3y)93.28%
Profit Quality(5y)84.36%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.3%
EPS Next 2Y13.11%
EPS Next 3Y13.25%
EPS Next 5Y12.69%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year9.17%
Revenue Next 2Y8.88%
Revenue Next 3Y9%
Revenue Next 5Y8.94%
EBIT growth 1Y20.53%
EBIT growth 3Y14.78%
EBIT growth 5Y14.44%
EBIT Next Year22.79%
EBIT Next 3Y14.89%
EBIT Next 5Y13.4%
FCF growth 1Y30.76%
FCF growth 3Y39.53%
FCF growth 5Y14.08%
OCF growth 1Y27.21%
OCF growth 3Y29.59%
OCF growth 5Y12.77%

IDEXX LABORATORIES INC / IDXX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?

ChartMill assigns a fundamental rating of 7 / 10 to IDXX.


What is the valuation status for IDXX stock?

ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.


What is the profitability of IDXX stock?

IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.


What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?

The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 42.91 and the Price/Book (PB) ratio is 27.74.


Can you provide the financial health for IDXX stock?

The financial health rating of IDEXX LABORATORIES INC (IDXX) is 8 / 10.